Trial Profile
A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (DUO)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Sep 2023
Price :
$35
*
At a glance
- Drugs Duvelisib (Primary) ; Ofatumumab
- Indications Chronic lymphocytic leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms DUO
- Sponsors Secura Bio
- 14 Dec 2021 Status changed from active, no longer recruiting to completed.
- 23 Feb 2021 This trial has been completed in Belgium, according to European Clinical Trials Database record.
- 29 Jan 2021 This trial has been completed in Austria according to European Clinical Trials Database record.